Pelthos Therapeutics Inc. (PTHS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Pelthos Therapeutics Inc. is a bio-pharmaceutical company formed via a July 1, 2025 merger between Channel Therapeutics Corporation and LNHC, Inc. The company commercializes three FDA-approved products: Zelsuvmi (molluscum contagiosum), Xepi (impetigo), and Xeglyze (head lice). Zelsuvmi was commercially launched in July 2025 and is the primary revenue driver. The company also maintains a clinical-stage pipeline targeting the NaV1.7 pain receptor.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Q2 2025 (3 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $15,603 | $26,509 | $0 | $0 |
| Net Product Revenue | $15,420 | $26,085 | $0 | $0 |
| Net Loss | $(23,417) | $(48,490) | $(3,449) | $(5,417) |
| Operating Loss | $(17,323) | $(30,411) | $(3,231) | $(5,065) |
| Cash and Cash Equivalents | $24,192 | $24,192 | $59 | $59 |
| Working Capital | $31,397 | $31,397 | N/A | N/A |
| Convertible Notes Payable (Fair Value) | $43,321 | $43,321 | $31,441 | $31,441 |
| Venture Loan (Principal) | $30,000 | $30,000 | $0 | $0 |
Note: Prior period comparisons are not directly comparable due to the July 1, 2025 merger and the subsequent launch of Zelsuvmi.
Material Changes and Operational Highlights
- Revenue Growth: Net product revenue grew 45% quarter-over-quarter (from $10.7M in Q1 2026 to $15.4M in Q2 2026), driven by Zelsuvmi commercialization.
- Restatement: The company restated its Q1 2026 financial statements due to a misapplication of ASC 820 regarding the fair value measurement of convertible debt. This resulted in a material weakness in internal controls.
- Debt Financing: In January 2026, the company entered a $50M Venture Loan and Security Agreement, drawing $30M. Based on trailing twelve-month revenue of $42.3M, the company believes it has achieved access to an additional $10M tranche.
- Inventory Write-off: The company recorded a $0.9M inventory write-off in Q2 2026 related to API batches that narrowly fell outside quality specifications.
- Convertible Debt Fair Value: A significant non-cash charge of $13.3M (YTD) was recorded for the change in fair value of convertible debt, driven by stock price changes and credit risk adjustments following the subordination of these notes to the new venture loan.
Guidance, Outlook, and Risks
- Liquidity: Management believes it has sufficient capital to fund operations for at least the next 12 months, citing cash on hand, forecasted Zelsuvmi sales, and access to the remaining venture loan facility.
- Product Launches: Xepi is expected to relaunch in Q1 2027, and Xeglyze in Q3 2027, pending supply chain and regulatory validation.
- Internal Control Weakness: The company identified a material weakness related to the accounting of complex convertible debt instruments. Remediation plans include engaging a specialized valuation firm and increasing accounting personnel expertise.
- Subordination Agreements: Milestone payments to Ligand ($10M accrued) and repayments of convertible notes are subordinated to the Venture Loan and cannot be made until specific criteria are met.
- Customer Concentration: Three wholesalers accounted for 82% of gross revenue in Q2 2026.
Investor Verification Checklist
- Restatement Impact: Verify the full extent of the Q1 2026 restatement and the specific valuation assumptions used for the convertible debt fair value.
- Debt Covenants: Review the specific milestones required to access the remaining $10M of the Venture Loan and the conditions for lifting the subordination on convertible notes and milestone payments.
- Inventory Quality: Assess the root cause analysis of the Q2 API quality issues and the status of subsequent manufacturing batches.
- Customer Concentration: Evaluate the risk associated with reliance on three wholesalers for 82% of revenue.
- Going Concern: Confirm the timeline for Xepi and Xeglyze launches, as delays could impact the revenue projections supporting the 12-month liquidity assertion.